| Amy Thurm, ARNP | |
|
905 Franklin St, Waterloo, IA 50703-4407 | |
| (319) 272-4300 | |
| Not Available |
| Full Name | Amy Thurm |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 905 Franklin St, Waterloo, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063896629 | NPI | - | NPPES |
| 0076372 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A126957 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Allen Hospital | Waterloo, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Physicians Clinic Medical Foundation | 8729992318 | 972 |
News Archive
MILabs BV has launched a complete new preclinical product line at the 2014 Annual European Association of Nuclear Medicine Meeting in Gothenburg, Sweden, October 18-22 (www.eanm.org). It consists of the new 4-series comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT incorporating significant improvements over the former PLUS-series. The 4-series carries even further the tradition of MILabs to deliver the best SPECT and PET image resolution available in the market.
Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.
Synexus' expansion in Central and Eastern Europe has been boosted with the acquisition of three more clinical trial centres in Poland.
Celsion Corporation today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).
› Verified 6 days ago
| Entity Name | Iowa Physicians Clinic Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366425274 PECOS PAC ID: 8729992318 Enrollment ID: O20031118000363 |
News Archive
MILabs BV has launched a complete new preclinical product line at the 2014 Annual European Association of Nuclear Medicine Meeting in Gothenburg, Sweden, October 18-22 (www.eanm.org). It consists of the new 4-series comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT incorporating significant improvements over the former PLUS-series. The 4-series carries even further the tradition of MILabs to deliver the best SPECT and PET image resolution available in the market.
Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.
Synexus' expansion in Central and Eastern Europe has been boosted with the acquisition of three more clinical trial centres in Poland.
Celsion Corporation today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).
› Verified 6 days ago
| Entity Name | Allen Memorial Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891772927 PECOS PAC ID: 4284546045 Enrollment ID: O20031211000480 |
News Archive
MILabs BV has launched a complete new preclinical product line at the 2014 Annual European Association of Nuclear Medicine Meeting in Gothenburg, Sweden, October 18-22 (www.eanm.org). It consists of the new 4-series comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT incorporating significant improvements over the former PLUS-series. The 4-series carries even further the tradition of MILabs to deliver the best SPECT and PET image resolution available in the market.
Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.
Synexus' expansion in Central and Eastern Europe has been boosted with the acquisition of three more clinical trial centres in Poland.
Celsion Corporation today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Thurm, ARNP 905 Franklin St, Waterloo, IA 50703-4407 Ph: () - | Amy Thurm, ARNP 905 Franklin St, Waterloo, IA 50703-4407 Ph: (319) 272-4300 |
News Archive
MILabs BV has launched a complete new preclinical product line at the 2014 Annual European Association of Nuclear Medicine Meeting in Gothenburg, Sweden, October 18-22 (www.eanm.org). It consists of the new 4-series comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT incorporating significant improvements over the former PLUS-series. The 4-series carries even further the tradition of MILabs to deliver the best SPECT and PET image resolution available in the market.
Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.
Synexus' expansion in Central and Eastern Europe has been boosted with the acquisition of three more clinical trial centres in Poland.
Celsion Corporation today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).
› Verified 6 days ago
Lisa Lynn Maher, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 419 East Donald Street, Waterloo, IA 50703 Phone: 319-236-1911 Fax: 319-287-5832 | |
Evans Komen, DNP,PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2750 Saint Francis Dr, Waterloo, IA 50702 Phone: 319-272-8922 Fax: 319-272-8929 | |
Dianna Kay Magginetti, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 905 Franklin St, Waterloo, IA 50703 Phone: 319-874-3000 | |
Irmela Salihovic, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2710 Saint Francis Dr Ste 320, Waterloo, IA 50702 Phone: 319-272-5000 Fax: 319-272-8072 | |
Ms. Amanda L. Vervaecke, A.R.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1825 Logan Ave, Wound & Ostomy Clinic, Waterloo, IA 50703 Phone: 319-235-3121 Fax: 319-226-2113 | |
Mr. Dieter J Boxmann, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 146 W Dale St, Suite 101, Waterloo, IA 50703 Phone: 319-233-3351 Fax: 319-233-3132 | |
Marcia A Rellihan, D.O. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3421 W 9th St, Suite G4500, Waterloo, IA 50702 Phone: 319-233-8865 Fax: 319-272-0400 |